Virtu Financial’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Virtu Financial’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-31,852	Closed	-$19K	–	2503
2022 Q2	$19K	Buy	31,852 +547	+2%	+$524	﹤0.01%	1349
2022 Q1	$41K	Buy	+31,305	New	+$50.7K	﹤0.01%	1181
2021 Q1	–	Sell	-28,821	Closed	-$97K	–	2239
2020 Q4	$97K	Buy	+28,821	New	+$103K	0.01%	1065
2019 Q4	$82K	Buy	+13,422	New	+$55.3K	0.01%	1121

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PTP

Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return

Virtu Financial's PHAS Position: Q3 2022 in Review

Virtu Financial sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2022, closing a stake of 31,852 shares — an estimated $19K sold.

Virtu Financial first reported a position in PHAS in Q4 2019 and held it in 4 quarters. The position peaked at $97K in Q4 2020. 38 funds tracked by Wall St. Rank hold PHAS as of Q3 2022.

Virtu Financial reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Virtu Financial sold 31,852 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $19K.
Virtu Financial first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
Virtu Financial's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $97K in Q4 2020.
38 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Virtu Financial's 13F filing for Q3 2022, filed 7 Nov 2022.